Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
Genscript Biotech Corporation (GNNSF) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Genscript Biotech Corporation $3.04, price $5.52, upside -44.9%, quality 56 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? No
- Good quality? Yes
- Add to watchlist
GB
Some data
Sep 24, 2026
Some data
Sep 24, 2026
Genscript Biotech Corporation
GNNSF · USStretched ValuationStrong overvaluation with only moderate quality.
!Fair value $3.04 · Strongly overvalued (−44.9%)
!Quality 56/100
!Mixed Growth (revenue 5y +19.7 %/yr)
!Loss-making · -55.5% net margin (TTM)
✓Low debt · generates free cash flow
!Narrow moat 28/100
!Evidence only medium, so the estimate is less certain
!The models disagree: range $1.79 to $5.64
Watch Genscript Biotech Corporation for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.
Watch for free
Pro now: $1 first month
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range $1.05 – $5.70 · fair‑value band $1.79 – $5.64 · the $5.52 price screens above the $3.04 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Company profile
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally.
Show more
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally. It operates through Life Science Services and Products; Biologics Development Services; and Industrial Synthetic Biology Products segments. The Life Science Services and Products segment provide research services and products which are used in fundamental to life-science research and application. The Biologics Development Services segment which helps biopharmaceutical and biotech companies accelerate the development of therapeutic antibodies, and gene/cell therapy products with an integrated platform. The Industrial Synthetic Biology Products segment develops and produces industrial enzymes through non-pathogenic microbial strains constructed using genetic engineering. It also offers SurePAGE, a precast gel series; CytoSinct, a Nanobeads product and services; and Benz-Neburase, a genetically engineered endonuclease. In addition, the company provides automated protein and antibody purification system; automated maxi-plasmid purification; automated mini-scale purification for plasmid, protein, and antibody; eBlot and eStain, a protein transfer and staining system; eZwest Lite, an automated western blotting device; CytoSinct, a cell isolation solution; pharmacokinetics and immunogenicity ELISA kits; COVID-19 detection cPass technology kits; and GenBox, a mini electrophoresis tank. It serves antibody drug discovery; gene therapy; vaccine; in vitro diagnostics; gene editing; plant biology; and synthetic biology solutions. The company was founded in 2002 and is headquartered in Wan Chai, Hong Kong.
Stock analysis
Genscript Biotech Corporation (GNNSF) currently trades at $5.52, while our model-based Fair Value estimate is $3.04, 44.9% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $3.00 per share, and 0 of the 13 models we run sit above the $5.52 price.
Bear case: the Earnings-Based group reads lowest at $1.01, and 13 of the 13 models stay below the price. Evidence for this calculation is medium.
Scenario range: $1.79 (bear) to $5.64 (bull), the price of $5.52 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 56/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Genscript Biotech Corporation reported revenue of $961M in FY2025 versus $511M in FY2021, a compound +17.1%/yr. Reported net income was −$534M in FY2025.
Key figures
Market cap $3.5B · P/S ratio 3.64 · EPS (TTM) $−0.2500 · Dividend yield 5.8% · Net margin −55.5% · Return on equity −12.9% · Return on assets (EBIT) −8.1% · Operating margin 17.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 3% below its 52-week high and 325% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −45%, GNNSF screens richer than that median.
Fair Value models
Bear $1.79
Fair Value $3.04
Bull $5.64
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF
$1.93
$2.94
$6.06
76
Growth DCF
$1.82
$3.21
$5.93
75
EPV
$0.8900
$1.01
$1.12
74
All 13 models by family
DCF Models
FCF DCF
$1.93
$2.94
$6.06
76
5Y Revenue Exit
$1.34
$2.18
$3.93
70
5Y EBITDA Exit
$1.78
$3.07
$5.60
72
10Y Revenue Exit
$1.50
$3.00
$3.89
66
10Y EBITDA Exit
$1.85
$3.92
$7.50
64
Earnings-Based
EPV
$0.8900
$1.01
$1.12
74
Multiples
EV/EBIT
$1.57
$2.07
$2.57
66
EV/EBITDA
$1.66
$2.19
$2.72
67
EV/Revenue
$1.00
$1.40
$1.79
54
Asset-Based
NCAV (Graham)
$0.9100
$1.21
$1.81
54
Growth DCF
Growth DCF
$1.82
$3.21
$5.93
75
Rev-Margin DCF
$1.39
$2.48
$4.62
69
Economic Profit
ROIC Compounder
$0.8900
$1.01
$1.12
72
Notify me when GNNSF reaches fair value
Put GNNSF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
56/100
Of which business quality 60 · Market factors (momentum, volatility) 81
Profitability
5
Margins and returns on capital today
Quality Growth
79
Are margins and returns improving?
Cashflow
89
Earnings quality: real cash, not paper profit
Fin. Strength
82
Balance sheet, leverage, solvency risk
Investment
21
Disciplined investing over empire-building
Low Volatility
38
Calm price path (market factor)
Momentum
100
Price trend over the last 3–12 months (market factor)
52W Momentum
98
Distance to the 52-week high (market factor)
Net Issuance
79
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
67/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+61.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.7%
Start year 2020 (pandemic). Over 10 years: +27.2% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+26.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−52.3% (2020) → 26.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+24.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+5.9%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +21.5% a year for the price and +3.4% for the forecasts.
Forecast 2026 (sales)−15.1%
Forecast 2027 (sales)+14.1%
Projected 2028 (sales)+12.6%
Projected 2029 (sales)+11.1%
Projected 2030 (sales)+9.6%
Earlier news
News mood ⓘNews mood, the average tone of recent news (95 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.
Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
- DNA Synthesis Market Outlook 2026-2035 - Featuring Profiles of Leading Companies Integrated DNA Technologies, GenScript Biotech, and Twist B
- Genscript Biotech Corp (GNNSF) (H1 2026) Earnings Call Highlights: Revenue Surges 27.3% to $404. ...
- GenScript and Tamarind Bio Partner to Connect AI Molecular Design with Rapid Lab Validation
- Genscript Biotech (SEHK:1548) Valuation Check After Recent Share Price Pullback
Compare Genscript Biotech Corporation with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 623 stocks
Beats the industry median on 9/11 measures
Overall it ranks above its industry peers.
Valuation Multiplesvs Biotechnology median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $527.67 | $580.44 | +10% |
| Regeneron Pharmaceuticals, Inc REGN | $752.25 | $1,275 | +69% |
| argenx SE ARGX | $959.49 | $918.60 | −4% |
| CSL Limited CSL | A$175.35 | A$192.89 | +10% |
| Samsung Biologics Co 207940 | 1,354,000 KRW | 1,489,400 KRW | +10% |
| BeOne Medicines AG ONC | $360.85 | $280.94 | −22% |
| Alnylam Pharmaceuticals, Inc ALNY | $255.96 | $217.88 | −15% |
| Royalty Pharma plc RPRX | $58.21 | $19.01 | −67% |
| Celltrion, Inc 068270 | 177,400 KRW | 74,519 KRW | −58% |
| WuXi Biologics (Cayman) Inc 2269 | HK$53.00 | HK$58.30 | +10% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is Genscript Biotech Corporation (GNNSF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $3.04 versus a price of $5.52, about −45% upside (overvalued).
What is the fair value of GNNSF?
Our model-based fair value for Genscript Biotech Corporation is $3.04 (as of Sep 24, 2026), built from audited fundamentals. The current price: $5.52.
What is the quality score of GNNSF?
Genscript Biotech Corporation has a Quality Score of 56/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Genscript Biotech Corporation (GNNSF)?
Our model-based price target is the fair value of $3.04 (as of Sep 24, 2026) from 13 valuation models. Cautious scenario $1.79, optimistic scenario $5.64. It is a calculation from audited fundamentals, not an analyst target.
What is the Genscript Biotech Corporation stock forecast for 2026?
Our models put fair value at $3.04, about −45% upside versus a price of $5.52 (overvalued). Cautious scenario $1.79, optimistic scenario $5.64. The calculation is refreshed regularly with new filings.
What is the revenue of Genscript Biotech Corporation (GNNSF)?
Genscript Biotech Corporation reported trailing-twelve-month revenue of about $960M (latest available figure, as of Sep 24, 2026).
Does Genscript Biotech Corporation pay a dividend?
Genscript Biotech Corporation currently shows a dividend yield of about 5.79% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Genscript Biotech Corporation (GNNSF)?
For today's price to be fair in a discounted-cash-flow model, Genscript Biotech Corporation would have to grow free cash flow by +24.4 % per year for five years (discount rate 9.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +19.7 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of GNNSF use?
Our models discount Genscript Biotech Corporation at 9.3 %: a base by market capitalisation (mid), damped by beta 0.83, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Genscript Biotech Corporation that is +24.4 % per year a year over ten years, using the same discount rate (9.3 %) and the same formula as our fair value.
How much growth has Genscript Biotech Corporation (GNNSF) delivered so far?
Over the past 5 years revenue at Genscript Biotech Corporation grew +19.7 % a year. The price currently implies +24.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Genscript Biotech Corporation (GNNSF) growing?
The median revenue growth in the sector is +5.2 % a year. That is the yardstick for the growth priced into Genscript Biotech Corporation (+24.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Genscript Biotech Corporation (GNNSF)?
The free-cash-flow yield on the price is 2.02 %: that much free cash flow Genscript Biotech Corporation produces per unit of market value. When it exceeds the discount rate of our models (9.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Genscript Biotech Corporation (GNNSF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Genscript Biotech Corporation it is $3.04 per share (as of Sep 24, 2026), against a price of $5.52. It is the blended result of 13 valuation models (cash flow, earnings, asset, dividend).
Is Genscript Biotech Corporation stock overvalued or undervalued in 2026?
As of Sep 24, 2026, GNNSF trades above its calculated fair value: price $5.52, fair value $3.04, a gap of about −45% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of GNNSF?
No. The price is what the market pays today ($5.52); the fair value is what the company's own numbers justify ($3.04). For Genscript Biotech Corporation the two are $2.48 per share apart. That gap is exactly why we show both numbers side by side.
How much is Genscript Biotech Corporation worth?
The market values Genscript Biotech Corporation at about $3.5B (market capitalisation, as of Sep 24, 2026). Per share that is $5.52; our models calculate a fair value of $3.04 per share.
What do the bullish and bearish scenarios say about GNNSF?
Our models span a range for Genscript Biotech Corporation: cautious scenario $1.79, base $3.04, optimistic $5.64 per share (as of Sep 24, 2026, price $5.52). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Genscript Biotech Corporation (GNNSF)?
Balance-sheet figures for Genscript Biotech Corporation (as of Sep 24, 2026): return on equity −12.9%. They feed the Quality Score of 56/100, which measures business quality independently of the share price.
How far is GNNSF from its 52-week high?
Genscript Biotech Corporation trades at $5.52, about 3% below its 52-week high of $5.70 and 325% above the low of $1.30 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $3.04 is for.
Which stocks are comparable to Genscript Biotech Corporation?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Genscript Biotech Corporation stock attractive at the current price?
The data as of Sep 24, 2026: price $5.52, calculated fair value $3.04 (−45%), Quality Score 56/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of GNNSF calculated?
We run Genscript Biotech Corporation through 13 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $3.04, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Genscript Biotech Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Genscript Biotech Corporation (GNNSF)?
The closing price on Oct 2, 2026 was $5.52. Our model-based fair value is $3.04, about −45% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Genscript Biotech Corporation right now?
The model range is unusually wide ($1.79 to $5.64). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (56/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Genscript Biotech Corporation
How large is the market capitalisation of Genscript Biotech Corporation (GNNSF)?
The market capitalisation of Genscript Biotech Corporation is $3.5B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Genscript Biotech Corporation (GNNSF)?
The price-to-sales ratio of Genscript Biotech Corporation is 3.64 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Genscript Biotech Corporation (GNNSF)?
Earnings per share at Genscript Biotech Corporation are $−0.2500. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Genscript Biotech Corporation (GNNSF)?
The dividend yield of Genscript Biotech Corporation is 5.8%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Genscript Biotech Corporation (GNNSF)?
The net margin of Genscript Biotech Corporation is −55.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Genscript Biotech Corporation (GNNSF)?
The return on equity (ROE) of Genscript Biotech Corporation is −12.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Genscript Biotech Corporation (GNNSF)?
On an EBIT basis the return on assets of Genscript Biotech Corporation is −8.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Genscript Biotech Corporation (GNNSF)?
The operating margin of Genscript Biotech Corporation is 17.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Genscript Biotech Corporation (GNNSF)?
Revenue at Genscript Biotech Corporation is growing +42.5% versus a year earlier (3y avg +15.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does Genscript Biotech Corporation (GNNSF) carry?
The net debt of Genscript Biotech Corporation is $350M (fiscal year 2025, ≈ 1.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Genscript Biotech Corporation in the live analysis
One click puts Genscript Biotech Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.